Asset profile
PDS0301 · PDS Biotechnology (PDSB)
- Indication
- MSS/pMMR metastatic colorectal cancer with liver metastases
- Also known as
- NHS-IL12, PDS01ADC
Company
PDSBPDS Biotechnology
PDSBPDS BiotechnologyPDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cance…
On the calendar
15
Oct 2026
Oct 15, 2026
7 days ago
PDSBPDS Biotechnology01
Dec 2028
Dec 1, 2028
in 771 days
PDSBPDS BiotechnologyTimeline
Newest first.
Oct 6, 2026
12:05 PM
PDSBPDS BiotechnologyPDS Biotech to Host KOL Event on PDS0301 in Advanced Colorectal Cancer with Liver Metastases
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04633252 | Phase 1/2 | Recruiting | Dec 31, 2026 | 86 | 1 of 1 sites in the United States |
| NCT04708470 | Phase 1/2 | Completed | May 6, 2025 | 55 | 1 of 1 sites in the United States |
| NCT04287868 | Phase 1/2 | Completed | Jul 26, 2022 | 51 | 1 of 1 sites in the United States |
| NCT05286814 | Phase 2 | Recruiting | Dec 31, 2027 | 70 | 1 of 1 sites in the United States |
| NCT04303117 | Phase 1/2 | Recruiting | Dec 1, 2028 | 80 | 1 of 1 sites in the United States |
| NCT05361798 | Phase 2 | Recruiting | Aug 1, 2027 | 65 | 1 of 1 sites in the United States |
| NCT04491955 | Phase 2 | Completed | Oct 25, 2022 | 32 | 1 of 1 sites in the United States |
| NCT06096870 | Phase 2 | Recruiting | Dec 31, 2028 | 65 | 1 of 1 sites in the United States |
More from PDS Biotechnology
Other drugs and candidates from the same company tracked in this sector.